Lyndra Therapeutics

Lyndra Therapeutics

  • Founded: 2015
  • Location: Watertown, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Schizophrenia/bipolar disorder
  • Drug types: PSY, END, CVV, ABU, INF, OBG
  • Lead product: LYN-005
  • Product link:
  • Funding: $60.5M C Jun 2021; $13M grant (Gates) Aug 2019; $55M B Jan 2019; $23M A Apr 2017

job board

Short description:

Drug Delivery

Drug notes:

LYN-045 Clin1 diabetes; LYN-047 Clin1 dyslipidemia; LYN-014 Clin1 (fast track) opioid use disorder; LYN-163 Clin1 malaria; LYN-006 Clin0 psychiatric conditions; LYN-013 Clin0 opioid use disorder; LYN-064 Clin0 contraception; undisclosed RD/Clin0 HIV

Long description:

Lyndra Therapeutics is working to make daily pills a thing of the past. Using their LYNXTM drug delivery platform, Lyndra is delivering long-acting therapies in oral form within a standard-sized capsule. The capsule contains the drug-containing element of the dosage form designed to elute drugs in an optimized way over a prolonged period. Lyndra’s technology has the potential for broad applicability across multiple therapeutic areas - including approved drugs and those currently in development. This includes programs for cardiometabolic diseases, women’s health and infectious diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy